There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Concert Pharma (NASDAQ: CNCE), Trevena Inc (NASDAQ: TRVN) and Sarepta Therapeutics (NASDAQ: SRPT) with bullish sentiments.
Concert Pharma (NASDAQ: CNCE)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Concert Pharma (NASDAQ: CNCE), with a price target of $26. The company’s shares closed yesterday at $19.68.
According to TipRanks.com, Fein is a 4-star analyst with an average return of 5.1% and a 47.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Strongbridge Biopharma Plc, and Cyclacel Pharmaceuticals.
Currently, the analyst consensus on Concert Pharma is Strong Buy and the average price target is $26.33, representing a 33.8% upside.
In a report issued on April 26, Mizuho Securities also maintained a Buy rating on the stock with a $27 price target.
Find more picks by Best Performing Analysts >>
Trevena Inc (NASDAQ: TRVN)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Trevena Inc (NASDAQ: TRVN) today and set a price target of $7. The company’s shares closed yesterday at $2.12.
According to TipRanks.com, Arce is a 5-star analyst with an average return of 18.5% and a 40.8% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Collegium Pharmaceutical, and Conatus Pharmaceuticals.
Currently, the analyst consensus on Trevena Inc is Moderate Buy and the average price target is $7, representing a 230.2% upside.
In a report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $5 price target.
Sarepta Therapeutics (NASDAQ: SRPT)
H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Sarepta Therapeutics (NASDAQ: SRPT) today and set a price target of $90. The company’s shares closed yesterday at $78.17, close to its 52-week high of $84.37.
According to TipRanks.com, Chattopadhyay is a 3-star analyst with an average return of 1.4% and a 45.9% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Mersana Therapeutics Inc, and Jounce Therapeutics Inc.
Currently, the analyst consensus on Sarepta Therapeutics is Strong Buy and the average price target is $93.33, representing a 19.4% upside.
In a report issued on April 19, Credit Suisse also maintained a Buy rating on the stock with a $100 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
